U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.Following the market opening Thursday, the Dow traded down 0.04% to 46,000.59 while the NASDAQ rose 0.49% to 22,370.12. The S&P 500 also rose, gaining, 0.29% to 6,619.34.Check This Out: This Target Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For ThursdayLeading and Lagging SectorsInformation technology shares jumped by 0.8% on Thursday.In trading on Thursday, materials ...

SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, ...

Market Overview - The market has experienced significant shifts, with several companies facing notable price declines due to sector-specific challenges and broader economic conditions [1] REX American Resources Corporation - REX American Resources Corporation's stock price has dropped over 50% to $30.54, facing potential operational challenges and broader market conditions affecting the Basic Materials sector [2] - The company's recent announcement regarding the conversion of REX-Osprey™ SOL + Staking ETF to a Regulated Investment Company structure may be a strategic move to enhance investor returns, but it may not have an immediate impact on REX's stock performance [2] Charles & Colvard, Ltd. - Charles & Colvard, Ltd. has seen a 42.65% decrease in its stock price to $0.43, facing challenges in the Luxury Goods and Consumer Cyclical sector [3] - The company's delisting from Nasdaq marks a significant change in its trading status, potentially contributing to the stock's decline [3] Bionano Genomics, Inc. - Bionano Genomics, Inc. experienced a 38.81% decline in its stock price to $1.69, specializing in genome analysis solutions [4] - Despite showcasing the utility of optical genome mapping in cancer biomarker analysis, market sentiment towards biotech investments and specific operational news may have contributed to the price drop [4] Osisko Development Corp. Warrant - Osisko Development Corp. Warrant saw a 32.43% decline to $0.25, with price movements influenced by fluctuations in gold prices and investor sentiment towards the Basic Materials sector [5] BT Brands, Inc. - BT Brands, Inc. experienced a 31.36% decline in its stock price to $0.31, operating in the quick-service restaurant industry [6] - The company faces challenges in the Consumer Cyclical sector, with market competition and broader economic factors affecting consumer spending potentially contributing to the stock's decline [6] Conclusion - The movements in these companies underscore the volatility and diverse factors influencing the market, with investors and analysts likely to monitor these developments for insights into the underlying causes of price changes and their potential long-term implications [7]

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday.The Dow traded down 0.37% to 45,713.02 while the NASDAQ fell 0.03% to 22,341.05. The S&P 500 also fell, dropping, 0.14% to 6,605.77.Check This Out: How To Earn $500 A Month From Darden Restaurants Stock Ahead Of Q1 EarningsLeading and Lagging SectorsEnergy shares jumped by 1.1% on Tuesday.In trading on Tuesday, utilities stocks fell by 0.8%.Top HeadlineDave & Buster's Entertainment Inc. P ...

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - The NASDAQ fell 0.03% to 22,341.05, and the S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - The company reported adjusted earnings of 40 cents per share, falling short of estimates of 92 cents per share [2] Commodity Market - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell by 0.1% to $4.7120 [5] European Market - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, London's FTSE 100 fell 0.74%, Germany's DAX 40 dipped 1.29%, and France's CAC 40 fell 0.72% [6] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series Warrants”), ...

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a catastrophic genomic event frequently associated with highly complex karyotypes, ext ...

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations relate ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potenti ...

Summary of Bionano Genomics FY Conference Call Company Overview - **Company**: Bionano Genomics (NasdaqCM: BNGO) - **Industry**: Biotechnology, specifically focusing on digital pathology and optical genome mapping Key Points and Arguments 1. **Transformation and Market Position**: Bionano Genomics has undergone a significant transformation over the past year, focusing on digitizing pathology processes and positioning itself as a digital pathology company [2][4] 2. **Market Opportunity**: The company estimates an available market of approximately $10 billion, consisting of around 10,000 labs processing about 10 million cases annually [4] 3. **Challenges with Traditional Methods**: Traditional cytogenetic methods like karyotyping are outdated, labor-intensive, and often yield limited clinical utility, with only about 50% providing useful information for therapy guidance [5][6] 4. **Optical Genome Mapping (OGM)**: OGM offers a faster, simpler workflow that consolidates multiple traditional methods into one, consistently finding more actionable variants compared to karyotyping [7][8] 5. **CPT Codes**: The establishment of Category 1 CPT codes by the American Medical Association for OGM in hematologic malignancies and constitutional genetic disorders enhances reimbursement prospects and adoption [8][9][21] 6. **Complementary Technology**: OGM is not in competition with sequencing but is complementary, allowing labs to run both technologies side by side for improved results [9][13] 7. **Product Portfolio**: The company offers a broad product portfolio, including the Stratus and Saphyr instruments, the Ionic Purification System, and VIA software, which enhances workflow efficiency [10][11][12] 8. **Focus on Routine Use Customers**: The strategy has shifted towards supporting existing customers who consistently purchase consumables, aiming to increase their utilization and profitability [17][18] 9. **Revenue Growth**: In 2025, the company reported mid-double-digit growth in consumables and software revenue from existing customers, with expectations for continued acceleration [19][20] 10. **Cost Structure Improvements**: Bionano Genomics has significantly reduced its operating costs and improved gross margins, achieving 52% in the second quarter of 2025 [22][23] 11. **Future Guidance**: The company has reiterated its annual revenue guidance of $26 million to $30 million and raised its guidance for new system installations from 15-20 to 20-25 [24] Additional Important Content - **Publications as Growth Indicators**: A record number of publications in the second quarter of 2025 indicates strong product usage and potential for attracting new customers [20][21] - **Geographic Focus**: Key markets include the United States, Canada, Western Europe, and Israel, where OGM has a strong foothold [5][14] - **Application Areas**: The primary application areas for OGM include hematologic malignancies, constitutional genetic diseases, and cell and gene therapy [14][16] This summary encapsulates the critical insights from the Bionano Genomics FY Conference Call, highlighting the company's strategic direction, market opportunities, and financial performance.